Synairgen Plc

0.59 (7.02%)
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.59 7.02% 8.99 190,628 15:30:24
Bid Price Offer Price High Price Low Price Open Price
8.40 8.99 8.99 8.40 8.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceutical Preparations 0.00 -48.66 -24.20 - 18.10
Last Trade Time Trade Type Trade Size Trade Price Currency
15:40:26 O 12,083 8.5062 GBX

Synairgen (SNG) Latest News

Synairgen (SNG) Discussions and Chat

Synairgen Forums and Chat

Date Time Title Posts
30/5/202314:39SNG - Amazing Short Now for 90%290
30/5/202308:36SNG001; a potential treatment for Covid 1971,132
23/5/202319:20Synairgen - a potential cure for Covid 19?24,070
23/4/202321:49Synairgen - Blockbusting potential119
08/3/202321:21SNG Blip in the Matrix is due 44.441,109

Add a New Thread

Synairgen (SNG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Synairgen (SNG) Top Chat Posts

Top Posts
Posted at 28/4/2023 11:02 by hazl
Trying to be clever I see.
I disregard the share price price action for the reason given.
It is you who are gloating.
I know someone with the condition and that's the reality.

Posted at 11/4/2023 09:00 by shoots101
Apologies there is no when. My error. I have complained to them that their decision not to keep shareholders informed breaches principle 10 of their own policy re comms to shareholders. That decision imo is to protect the share price further as to me it's obvious they don't have any good news around the corner. They should absolutely be communicating with shareholders .
Posted at 21/3/2023 14:37 by frankistaien
Gunto, I simply love seeing you losing your shirt.
After many months of ill advices, crazy ramping, and deceit on multiple boards finally you are getting paid back.
You and many on lse (Sharedealer2019, Tommy, Duncan, andycap,...) like squaddies attacked, for months, everyone who used to cast any shadow of doubt on SNG, now your very basic investment skills have totally emerged.
Like Shoots said, many investors were right at selling after the p3, at calling the single digit share price,.. while you, and all the posters above mentioned were unjustifiably attacking them.
Gunto, it's pay back time for you, I'm afraid.

Posted at 20/2/2023 20:32 by shoots101
Lol lol lol. Gunt or is it Al. its truly excellent work and fantastic news. So so fantastic that the share price went down today. Lol lol. Sng using that superlative also demonstrates just how desperate they are now. Next they will say its fantastic that SNG have invested in a new microscope lol lol. You gotta laugh. What a company. As for Gunt, just boringly so so transparent young man but hilarious at the same time. Hazel Im sure youre seeing the light now as he couldn't make it anymore obvious.
Posted at 06/2/2023 22:04 by lucifer7

Posted in: SNG

Posts: 491

Price: 16.01

No Opinion

RE: Key points from Manifesto.16 Dec 2022 18:17
STRIVE will move forward. SNG are either on it or they aren’t. I believe they will be on it.



Posted in: SNG

Posts: 491

Price: 18.00

No Opinion

RE: Letting the days go by...16 Nov 2022 21:09
STRIVE was meant to kick off in August. We are in November and only one protocol has been signed off. If SNG001 is going to be part of the second protocol which is just around the corner, then we could easily be looking at an early 2023 start.

Posted at 04/2/2023 11:19 by shoots101
Just to add there is no evidence of sng being accepted onto any trial. Sadly quite the opposite and Im afraid Gunto and the like simply dont have the understanding of the sheer volume of other competitors now as they continue to have blinkers very firmly in place. Just keeping it real. If sng does get on a trial and thats a big IF you can expect a small bump in share price but thats it really imo. Another big clue is Sir Stephen Holgate total disappearance to sng. ATB
Posted at 02/11/2022 08:27 by the_paladin
Synairgen are currently very focused on securing another P3 equivalent trial. I am interested in the nature of any available trial in principle, and how they would apply to SNG001?

1. The trial protocols?
2. The time scale?
3. The cost to Synairgen, and their degree of involvement in the trial?
4. What effect would a firm acceptance on a suitable trial have on the share price?
5. What would the share price be at the successful conclusion of a trial?
6. What role TFG Asset Management might play?
7. Would trial inclusion induce any interest from a BP company ?
8. These questions are simplistic, and a trial’s circumstances would change according to its nature (Joint Venture or Platform Trial?).
9. Bearing in mind the conduct of previous trials, the trial design, and the conditions under which it is executed are very important. SNG001 must be given the best opportunity to succeed next time around.

Before this conversation or any recent conversation becomes relevant, Synairgen must first secure a place on a trial. Otherwise another fund raise to finance a trial, with associated share price dilution may be necessary. To end on a positive note, there has been an aggregate of positive trial data and results recently, and the latter has been presented well to significant audiences at international conferences.

From their recent statements, Synairgen are hopeful of a successful outcome to the latter.

“We aren’t disclosing the specifics of our discussions and applications with specific trials but as soon as we have a concrete trial or trials agreed we will make an announcement.“


Posted at 13/10/2022 15:32 by the_paladin
Thanks gunto.

Any comments cautioning me about my Synairgen investment prior to the Sprinter results would have been very welcome. One does spring to mind, that being Doc83 on the LSE board whose “share price of £10 or 10p” post trial comment proved to be accurate, sadly at the wrong end of the scale. There is little point in cautioning investors now when their portfolios are significantly depreciated. There is a massive risk to reward factor present when investing in an AIM biotechnology company. We all knew that at the outset. Anyone, who thought that the promising data sets issued by Synairgen in recent months would result in a share price increase were mistaken. Should this significant data cluster attract attention resulting in a new P3 equivalent trial, itwill have served its purpose. It is only another trial(a JV with a BP company or Strive are possibilities? ) that would result in a share price increase. Investors can only remain hopeful at this point in time. We all risked our capital, as is the case with all investments. Time will tell whether we will be rewarded in the future? For sure, had I sold my stock, I would have only have consolidated my losses! I prefer remaining with my Synairgen investment as things stand. ATB with your investment decisions.

Posted at 12/10/2022 12:57 by the_paladin
For transparency, I have changed my pseudonym from Dodobird25 to The_Paladin. The latter is also used elsewhere.

I am focused on the company achieving a trial invitation. Strive or a JV with a BP company are at the forefront of my mind?
I am assuming a Covid-19 trial, although it may be something different ? Some questions occurred to me about this:

a) The recruitment of a sufficient number of severely unwell patients to provide statistically significant data to verify SNG001’s efficacy? This has been our major issue in the past. We need to demonstrate the latter when patients who receive SNG001 treatment, and placebo patients, are both being treated with an appropriate SOC at the same time. How can Synairgen ensure that the trial is a fair test if it is conducted in multiple countries, with different SOC, and with some patients being allowed to leave the trial before all doses are administered? These factors may well have contributed to our lack of success in February?

b) Wearing my investor hat, will there be a significant upgrade to the share price should we achieve a further major trial? The answer to that question is surely yes? Following the start of the Sprinter trial, the share price met several bumps along the road. With the first vaccine approval, the share price declined to 80p or thereabouts. There was a short P&D raid when The Lancet P2 peer review was published, but the share price declined again shortly afterwards. There was a similar decline following the P2 Home Webinar the following February . The share price recovered well from that point by the end of 2021.

Is it therefore reasonable to assume that a place on a major trial, and with it a route to commercialisation, might well give us a x4 uplift back to the 80-90p range? It is logical to think that this could happen?

With my realist hat still in place, I fully appreciate that we will remain where we are unless an incoming trial emerges, or BP expressed a wish to acquire the company? Both alternatives would give us a good reason to be cheerful in my opinion.

Posted at 07/9/2022 07:14 by blakieboy7
RNS Number : 5162YSynairgen plc07 September 2022Synairgen plc('Synairgen' or the 'Company')Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patientsSouthampton, UK - 7 September 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces positive data from additional assessments of lung sputum samples from its Phase 2 clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection ( SG015, NCT03570359 ).In early 2020, due to the emergence of SARS-CoV-2, Synairgen's SG015 trial in COPD patients was paused with 109 out of the targeted 120 patients recruited. An interim analysis of the data was reported in September 2020 which demonstrated that SNG001 boosted lung antiviral responses as assessed using sputum biomarkers, and led to a significant difference in the lung function of exacerbating patients. ([1])Key findings of the additional assessment include: -- Viral clearance from the lower respiratory tractSputum samples were collected where possible at study visits conducted during and after the 14-day dosing period. Assessment of viral clearance focused on the most frequently detected virus, human rhinovirus (HRV), which accounted for approximately 50% of infections. The results suggest that HRV was cleared more rapidly in patients treated with SNG001 than placebo with a statistically significant difference in the proportion of patients with detectable HRV in sputum at Day 7 (post hoc analysis). -- Markers associated with secondary bacterial infectionsIn COPD exacerbations, sputum purulence and elevated levels of serum C-reactive protein (CRP) are associated with the presence of bacteria in the lower respiratory tract. In the second week of treatment, a greater proportion of patients in the placebo group had purulent sputum or elevated serum CRP.Richard Marsden, CEO of Synairgen , said: "Our new data from COPD patients shows that SNG001 can accelerate viral clearance from the lung and builds on our existing data supporting SNG001's mechanism of action and our focus on severe viral lung infections. This additional assessment supports continued and further investigation of SNG001 as a possible broad-spectrum antiviral."The new findings are included in a presentation today entitled, "Don't be resistant to going antiviral: Could a broad-spectrum inhaled antiviral reduce the incidence of secondary bacterial chest infections?" by Richard Marsden at the World Anti-Microbial Resistance Congress in National Harbor, Maryland, USA.
Synairgen share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230530 15:04:56